| Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hospitalisation for cardiovascular causes | no data |
| death from cardiovascular causes or hospitalization for cardiovascular causes | no data |
| serious hyperkalemia | no data |
| Sudden death | no data |
| death from cardiovascular causes or hospitalization for heart failure | no data |
| Death from any cause or hospitalization for any reason | no data |
| exacerbation of heart failure | no data |
| NYHA class improvement | no data |
| Death from any cause or hospitalization for heart failure | no data |
| Cardiovascular death | no data |
| hospitalisation for heart failure | no data |
| All cause death | no data |
| Hospitalization for any reason | no data |
| Adverse events leading to treatment discontinuation | no data |
| Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients
